Wednesday, June 19, 2013

Prandin Litigation -Federal circuit rules in favor of Sun Pharma / Caraco

In the ongoing Prandin Litigation, the Federal Circuit has affirmed a lower court's ruling that a patent covering Novo Nordisk A/S' diabetes treatment Prandin is invalid as obvious, handing a victory to generics makers Caraco Pharmaceutical Laboratories Ltd. and Paddock Laboratories Inc.
  
Prandin has annual sales of approximately US$230 million in the US .  Sun Pharma was the first to file on Prandin and hence would enjoy a 180-day exclusivity on Prandin. A final USFDA approval is still pending for Caraco / Sun.


Enter your email address:


Delivered by FeedBurner